aspirin; carisoprodol - Profile

What are the generic drug sources for aspirin; carisoprodol and what is the scope of patent protection?

Aspirin; carisoprodol is the generic ingredient in five branded drugs marketed by Chartwell Rx, Genus, Novast Labs, Oxford Pharms, Watson Labs, Meda Pharms, Ingenus Pharms Nj, and Sandoz, and is included in ten NDAs. Additional information is available in the individual branded drug profile pages.

Summary for aspirin; carisoprodol

US Patents:	0
Tradenames:	5
Applicants:	8
NDAs:	10

US Patents and Regulatory Information for aspirin; carisoprodol

Applicant	Tradename	Generic Name	Dosage	NDA	Approval Date	TE	Type	RLD	RS	Patent No.	Patent Expiration	Product	Substance	Delist Req.	Exclusivity Expiration
Chartwell Rx	CARISOPRODOL AND ASPIRIN	aspirin; carisoprodol	TABLET;ORAL	089594-001	Mar 31, 1989		DISCN	No	No
Genus	CARISOPRODOL AND ASPIRIN	aspirin; carisoprodol	TABLET;ORAL	040116-001	Apr 25, 1996		DISCN	No	No
Novast Labs	CARISOPRODOL AND ASPIRIN	aspirin; carisoprodol	TABLET;ORAL	040832-001	Jan 7, 2010		DISCN	No	No
Oxford Pharms	CARISOPRODOL AND ASPIRIN	aspirin; carisoprodol	TABLET;ORAL	040252-001	Dec 10, 1997		DISCN	No	No

Expired US Patents for aspirin; carisoprodol

Applicant	Tradename	Generic Name	Dosage	NDA	Approval Date	Patent No.	Patent Expiration
Meda Pharms	SOMA COMPOUND	aspirin; carisoprodol	TABLET;ORAL	012365-005	Jul 11, 1983	4,534,973

Analysis of Aspirin and Carisoprodol: Patent Landscape and Investment Fundamentals

Last updated: February 19, 2026

This analysis examines the patent landscape and investment fundamentals of two pharmaceutical drugs: aspirin and carisoprodol. Aspirin, a widely recognized analgesic and anti-inflammatory, has a long history with expired patents. Carisoprodol, a muscle relaxant, has a more recent patent history and different market dynamics.

What is the Patent Status of Aspirin?

Aspirin, chemically known as acetylsalicylic acid, was first synthesized in the 19th century. Its foundational patents expired decades ago.

• Original Patent Filing: The first patent related to acetylsalicylic acid was filed by Felix Hoffmann of Bayer in 1897.
• Patent Expiration: U.S. patents for aspirin expired by the early to mid-20th century. For example, U.S. Patent 644,077, granted in 1900, covering the acetylation of salicylic acid, has long since expired.
• Generics Dominance: The expiration of primary patents has led to widespread generic availability of aspirin. The market is characterized by low manufacturing costs and intense price competition among generic manufacturers.
• Current Intellectual Property: While the core compound is off-patent, limited new intellectual property may exist for specific formulations, delivery methods, or novel therapeutic uses, though these are not the basis of the drug's widespread current use.

What are the Investment Fundamentals of Aspirin?

Aspirin's investment profile is characterized by its status as a mature, off-patent commodity drug.

• Market Size: The global aspirin market is substantial, driven by its broad use as an over-the-counter (OTC) pain reliever, anti-inflammatory, and for cardiovascular prevention (low-dose aspirin). The market is measured in billions of dollars annually.
• Revenue Drivers: Revenue is primarily generated through high-volume sales of generic aspirin products. Manufacturers compete on cost efficiency and distribution reach.
• Profitability: Profit margins on generic aspirin are generally low due to intense competition and price sensitivity. Companies in this space rely on scale and operational efficiency for profitability.
• Growth Potential: Significant growth in the core aspirin market is limited. Expansion opportunities may arise from specialized formulations or expanded indications, but these are unlikely to drive substantial new revenue streams compared to novel drug development.
• R&D Investment: Research and development investment in aspirin by major pharmaceutical companies is minimal, focusing on process improvements or minor formulation tweaks rather than significant new drug discovery.
• Competitive Landscape: The competitive landscape is fragmented, with numerous generic manufacturers globally. Major players often have diversified portfolios that include aspirin as a staple product.
• Regulatory Environment: Aspirin is well-established and regulated by health authorities worldwide (e.g., FDA, EMA). Its OTC status simplifies some regulatory hurdles compared to prescription drugs.
• Investment Thesis: Investment in aspirin is primarily for companies with significant manufacturing scale, efficient supply chains, and established distribution networks for generic pharmaceuticals. It is not a growth-stage investment but a component of a stable, high-volume generics business.

What is the Patent Status of Carisoprodol?

Carisoprodol is a centrally acting skeletal muscle relaxant. Its patent history is more recent than aspirin's.

• Original Patent Filing: Carisoprodol was developed by Wallace Laboratories. The original U.S. patent for carisoprodol was U.S. Patent 2,937,119, filed in 1955 and granted in 1960. This patent covered the compound itself.
• Patent Expiration: The primary compound patent for carisoprodol expired in 1977.
• Formulation and Use Patents: Subsequent patents may have covered specific formulations, manufacturing processes, or therapeutic uses. For instance, patents might have addressed controlled-release formulations or specific treatment protocols.
• Generics Entry: Following the expiration of its core patent, generic versions of carisoprodol entered the market.
• Market Control and Abuse: The drug has faced scrutiny and scheduling by regulatory bodies due to its potential for abuse, which has influenced its market dynamics and prescription patterns. This has led to some countries reclassifying it, impacting its commercial viability. For example, in 2012, the U.S. Drug Enforcement Administration (DEA) classified carisoprodol as a Schedule IV controlled substance.

What are the Investment Fundamentals of Carisoprodol?

Carisoprodol's investment fundamentals are more complex due to its classification, prescription status, and therapeutic niche.

• Market Size: The market for carisoprodol has been significant but is subject to fluctuations driven by regulatory actions and the availability of alternative muscle relaxants. The market size, while historically substantial, is not comparable to blockbuster drugs.
• Revenue Drivers: Revenue is generated from prescription sales of both branded (e.g., Soma) and generic carisoprodol. Prescriber behavior and patient access are key drivers.
• Profitability: Profitability for manufacturers depends on their position in the branded or generic market. Branded products may command higher margins, but generic competition erodes pricing power. Regulatory controls and the risk of abuse can also impact revenue stability.
• Growth Potential: Growth potential for carisoprodol is constrained. Its therapeutic niche is limited to muscle relaxation, and its use is often short-term. Regulatory hurdles and the availability of alternative therapies with better safety profiles (e.g., baclofen, cyclobenzaprine) limit expansion.
• R&D Investment: R&D investment by originator companies focused on carisoprodol is likely minimal, concentrated on lifecycle management if applicable, or shifted to newer therapeutic areas. Generic manufacturers may invest in process optimization.
• Competitive Landscape: The market includes the original branded product and multiple generic manufacturers. Competition exists from other muscle relaxants with different pharmacological profiles and regulatory statuses.
• Regulatory Environment: Carisoprodol's status as a controlled substance (Schedule IV in the U.S.) imposes significant regulatory requirements on manufacturing, distribution, prescribing, and dispensing. This adds compliance costs and complexity.
• Abuse Potential and Safety Concerns: The drug's potential for abuse and dependence, coupled with its metabolism into meprobamate (a known sedative), has led to increased regulatory oversight and a trend towards more cautious prescribing, impacting market demand.
• Investment Thesis: Investment in carisoprodol is higher risk than aspirin. It requires an understanding of controlled substance regulations, prescriber behavior, and the evolving landscape of pain management and muscle relaxant alternatives. Companies with expertise in controlled substance pharmaceuticals or a diversified portfolio of established generics may consider it. However, its long-term growth prospects are uncertain due to its inherent risks and therapeutic limitations.

Comparative Analysis: Aspirin vs. Carisoprodol

Feature	Aspirin	Carisoprodol
Drug Class	Nonsteroidal Anti-inflammatory Drug (NSAID), Analgesic	Skeletal Muscle Relaxant
Primary Use	Pain relief, anti-inflammation, cardiovascular prevention	Muscle pain and spasms
Patent Status	Expired, generic commodity	Core patent expired, some formulation/use patents possible
Market Access	Primarily Over-the-Counter (OTC)	Prescription-only, controlled substance (e.g., Schedule IV)
Regulatory Burden	Low (OTC status)	High (controlled substance regulations)
Competition	Intense generic price competition	Generic competition + competition from alternative muscle relaxants
Growth Potential	Limited, mature market	Limited, constrained by therapeutic niche and regulatory issues
Risk Profile	Low, established safety profile	Moderate to High, due to abuse potential and regulatory changes
Typical Investor	Generics manufacturers, large-cap pharma	Niche generics manufacturers, companies with controlled substance expertise

Aspirin: Fundamentals and Investment Considerations

Aspirin is a cornerstone of global pharmacotherapy, characterized by its ubiquitous availability and low cost. Its market is mature, with established demand driven by its multifaceted therapeutic applications, including analgesia, anti-inflammation, and cardioprotection at low doses. The absence of patent protection means the market is dominated by generic manufacturers, leading to a highly competitive environment focused on operational efficiency and supply chain optimization.

• Market Dynamics: Demand for aspirin remains robust due to its effectiveness, accessibility, and affordability. Its over-the-counter (OTC) status further contributes to high-volume sales.
• Profitability Drivers: For manufacturers, profitability in the aspirin market is directly correlated with economies of scale, efficient production processes, and effective distribution. Price wars are common among generic suppliers.
• Investment Attractiveness: Companies investing in aspirin are typically seeking stable, high-volume revenue streams within their generics portfolios. Growth opportunities are modest, primarily arising from market share gains through cost leadership or expansion into emerging markets where access to essential medicines is a priority. Research and development expenditure is minimal, focused on incremental process improvements rather than novel discovery.

Carisoprodol: Fundamentals and Investment Considerations

Carisoprodol represents a different investment profile, situated within the prescription drug market and subject to significant regulatory scrutiny due to its potential for misuse. Originally patented, its compound patent has expired, allowing for generic competition. However, its classification as a controlled substance (e.g., Schedule IV in the U.S.) imposes stringent controls on its distribution and prescription, impacting market access and contributing to a higher risk profile.

• Market Dynamics: The market for carisoprodol is influenced by prescriber habits, patient needs for muscle spasm relief, and the availability of alternative treatments. Regulatory actions, such as scheduling, can dramatically alter market dynamics and reduce prescribing.
• Profitability Drivers: Profitability for carisoprodol manufacturers is affected by generic pricing pressures, manufacturing compliance costs associated with controlled substances, and the overall volume of prescriptions written. Brand loyalty may offer some margin support for originator products, but this is increasingly challenged by generics.
• Investment Attractiveness: Investment in carisoprodol is more speculative. Companies with demonstrated expertise in navigating the complexities of controlled substance regulations, manufacturing, and compliance may find opportunities. However, the long-term market outlook is challenged by evolving treatment guidelines, the emergence of safer alternatives, and ongoing regulatory oversight. R&D investment is typically limited to process optimization for generics or lifecycle management for branded products, if applicable.

Key Takeaways

Aspirin is a mature, off-patent commodity drug with stable, high-volume demand. Investment is driven by manufacturing scale and cost efficiency, offering low margins but predictable revenue. Carisoprodol, a prescription muscle relaxant, faces a more complex market due to its controlled substance status, leading to higher regulatory burdens and a constrained growth outlook. Investment in carisoprodol carries elevated risk associated with regulatory changes and therapeutic alternatives.

Frequently Asked Questions

1. Are there any active patents that could significantly impact the market for aspirin? While the core compound patent for aspirin has long expired, new patents might exist for specific advanced drug delivery systems, novel formulations (e.g., delayed-release, enteric-coated), or specific therapeutic combinations. However, these are unlikely to fundamentally alter the market dynamics of standard aspirin products.

2. What are the primary regulatory challenges associated with manufacturing and distributing carisoprodol? The primary regulatory challenge is its classification as a controlled substance. This necessitates strict adherence to regulations concerning production quotas, secure storage, detailed record-keeping of all transactions, controlled distribution channels, and compliance with prescribing and dispensing guidelines set by agencies like the DEA in the United States.

3. How does the risk profile of investing in aspirin compare to investing in carisoprodol? Investing in aspirin carries a low risk profile, primarily associated with competitive pricing pressures and market volume fluctuations in the generics sector. Investing in carisoprodol involves a higher risk profile due to potential regulatory actions (scheduling changes, prescribing restrictions), the drug's abuse potential, and competition from alternative, potentially safer, muscle relaxants.

4. What are the key drivers of demand for carisoprodol in the current market? Demand for carisoprodol is driven by physician prescriptions for acute muscle pain and spasms. However, this demand is increasingly tempered by awareness of its abuse potential, regulatory controls that limit accessibility, and the availability of alternative treatments with perceived better safety profiles.

5. Beyond core patents, what other intellectual property could a company hold related to aspirin or carisoprodol? For aspirin, intellectual property might extend to specific polymorphs, novel salt forms, advanced manufacturing processes ensuring high purity, or unique combinations with other active pharmaceutical ingredients for specific therapeutic indications. For carisoprodol, intellectual property could include novel crystalline forms, specific prodrugs, or sophisticated combination therapies targeting related neurological or musculoskeletal conditions, although these are less common given the drug's established profile.

---

Sources

[1] U.S. Patent 644,077. (1900). Process of making acetylsalicylic acid. Felix Hoffmann. [2] U.S. Patent 2,937,119. (1960). Amides of 2-substituted-2-propyl carbamic acids. Frank J. Villani. [3] U.S. Drug Enforcement Administration. (2012, October 11). Schedules of controlled substances: Placement of carisoprodol into Schedule IV. Federal Register.